3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
43
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
12
Sarcoma
8
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Lymphoma
5
Glioblastoma
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, Non-Hodgkin
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Dexamethasone
21
Calcium Dobesilate
10
Melphalan
9
Bortezomib
8
Cyclophosphamide
7
Lenalidomide
6
pomalidomide
4
miridesap
3
daratumumab
3
venetoclax
2
ixazomib
2
belantamab mafodotin
2
Thalidomide
2
Doxycycline
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
isatuximab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
birtamimab
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Pharmaceutical Preparations
1
Lisaftoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Amyloidosis
×
selinexor
×
Clear all
NCT04984330
2022-11-17
STARR
Weill Medical College of Cornell University
Phase EARLY_PHASE1
Withdrawn